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SupersaturationSolid dispersion technology represents a successful approach to addressing the bioavailability issues
caused by the low aqueous solubility of many Biopharmaceutics Classification System (BCS) Class II
drugs. In this study, the use of high-yield manufacture of fiber-based dispersion is explored as an alter-
native approach to monolith production methods. A temperature-controlled solvent-free centrifugal
spinning process was used to produce sucrose-based microfibers containing the poorly water-soluble
drugs olanzapine and piroxicam (both BCS Class II); these were successfully incorporated into the micro-
fibers and the basic characteristics of fiber diameter, glassy behavior, drug loading capacity and drug–
sucrose interaction assessment were measured. Scanning electron microscopy revealed that bead-free
drug-loaded microfibers with homogenous morphology and diameter in the range of a few micrometers
were prepared using our process. Differential scanning calorimetric and X-ray diffraction analyses
showed that both drug and carrier were present in the amorphous state in the microfibers, although
in the case of piroxicam-loaded microfibers, the presence of small amounts of crystalline drug was
observed under polarized light microscopy and in Fourier transform infrared spectra. Drug dissolution
performance was evaluated under both sink and non-sink conditions and was found to be significantly
enhanced compared to the corresponding crystalline physical mixtures and pure drugs, with evidence
of supersaturation behavior noted under non-sink conditions. This study has demonstrated that
microfiber-based dispersions may be manufactured by the centrifugal spinning process and may possess
characteristics that are favorable for the enhanced dissolution and oral absorption of drugs.
 2016 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The improvement of drug dissolution performance of poorly
water-soluble active compounds remains a key challenge in the
field of pharmaceutical technology. High-throughput screening in
non-aqueous solutions, the application of combinatorial chemistry
as well as the desire to increase drug potency via increasing recep-
tor binding mediated by hydrophobic interactions, have all led to a
dramatic increase in new drug candidates with low water solubil-
ity [1–3]. The majority of these compounds belong to class II (low
solubility and high permeability/high metabolism) within the Bio-
pharmaceutics Classification System (BCS) and BiopharmaceuticsDrug Disposition Classification System (BDDCS). It has been esti-
mated that up to 75% of drugs currently under development will
have poor solubility in water, which clearly affects the potential
for drug absorption after oral administration [4].
Several approaches have been developed for the enhancement
of the dissolution rate and in turn oral bioavailability of poorly
water-soluble drugs, including solid dispersions [5–7]. These are
dispersions of one or more ingredients in a solid form of continu-
ous matrix/carrier prepared by solvent, melting or solvent-
melting methods. The increase in the drug dissolution rate from
solid dispersions has been attributed to several factors, such as
reduction in drug particle size, solubilization properties of the car-
rier material, enhanced wettability and dispersability of the drug
by the carrier and conversion to the amorphous form of the drug
[8]. In particular, solid dispersions containing the drug in the amor-
phous state have generally shown to lead to a significant enhance-
ment of dissolution rate compared to formulations containing the
drug in the crystalline state, due to the reduction/elimination of
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the great potential of this approach, solid dispersions are still an
‘under-realized’ tool, mostly due to their physical instability
and difficulties associated with high cost production as well as
up-scaling of the final product [9].
The majority of studies that use solid dispersion technologies
have involved the production of monolith systems using methods
such as hot melt extrusion (HME); such approaches have potential
in terms of both efficiency and feasible scale up to production levels
and relevant examples include Isoptin SRE-240 and Kaletra
tablets (Abbott Laboratories) [10]. Recently, the idea of combining
solid dispersion technology and nanotechnology has started to
attract interest within the field, notably in terms of the production
of solid dispersions in the form of nanofibers using techniques such
as electrospinning [11–13]. Nanofibers have been extensively stud-
ied for awide range of applications, including filtration [14], protec-
tive clothing [15], tissue engineering [16] and sensors [17]. Their use
in the drug delivery field has increased dramatically over recent
years due to evidence for greater drug dissolution enhancement
compared to conventional solid dispersion-based formulations,
such as the case of electro-spun spironolactone [13] and itracona-
zole [18]. Indeed, studies to date using electrospinning have sug-
gested that the particular porous structure and high surface area/
volume ratio of nanofibers may represent key advantages to over-
coming the drug solubility and bioavailability concerns of many
drugs. However, the application of electrospinning within the phar-
maceutical field has been limited by poor cost–yield efficiency due
to the complexity of the production process and low production
rates, despite the development of scale-up approaches including
multi-nozzle [19], nozzle-free [20] and high speed electrospinning
[18].
In this study, we explore the use of an alternative fiber produc-
tion approach as a means of producing solid dispersions, namely
centrifugal spinning. This approach, patented by Hooper in 1924,
is a well-known extrusion process which has been widely used
for the manufacture of micrometer-scale glass fibers for more than
half a century [21], as well as being widely used in the confec-
tionary industry. Centrifugal spinning is a one-step top-down tech-
nique, whereby material is placed into a preheated or room
temperature rotating metal container (spinning head) with side
nozzle holes or gap between two plates, which rotates at high
speed (generally in the range of 2000–13,000 rpm). The centrifugal
force generated at high rotation speed pushes the spinning fluid
through the holes of the spinning head. While the spinning fluid
is ejected, it undergoes a stretching process due to air friction force
followed by fast air solidification by cooling or solvent evaporation
and formation of extruded fibers in the range of nano or micro
scale [22,23]. The centrifugal force (Fc) and air friction force (Ff )
are described by Eqs. (1) and (2) [24]:
Fc ¼ mx2s Ds=2 ð1Þ
Ff ¼ pCqAx2j D2j =2 ð2Þ
where m is the mass of the molten material, C is a numerical drag
coefficient, q is the air density, and Ais the cross sectional area of
the jet; xs, Ds, xj, and Dj, are the rotating speed and diameter of
the spinneret and the jet respectively. Therefore, centrifugal and
air friction forces increase as the rotation speed increases, which
in turn leads to greater stretching of the liquid jet and reduction
in fiber diameter.
Many studies have shown that centrifugal spinning is a valid
alternative approach to producing nanofibers from a wide range
of materials at high rate and low cost due to simple equipment
set-up, solvent-free capability and no need of use of high voltage
[24]. Relevant examples are ForcespinningTM [25], rotary jet spin-
ning [26] and pressurized gyration [27]. It is also noteworthy thatduring the centrifugal spinning process, materials are spun very
quickly (a few seconds); therefore, the brief residence time of
material exposed to high temperatures should reduce the risk of
material degradation [28]. It is therefore logical to explore the
use of centrifugal spinning processes as a means of producing solid
dispersions, given the high surface area generated which may
potentially further enhance dissolution advantages. Table 1 com-
pares the technological aspects of the most common methods for
the manufacture of solid dispersions with electrospinning and
the centrifugal spinning process [25–27,29,18,30–34].
Inspection of this table indicates that nanofibers can be pro-
duced at high rates using the centrifugal spinning method for var-
ious applications. This leads to the suggestion that the use of this
approach could be extended into the pharmaceutical industry for
the preparation of solid dispersions. However, perhaps surpris-
ingly, studies to date on drugs incorporated into nanofibers by cen-
trifugal spinning are still very limited. One notable approach has
been the production of Flash Dose tablets using ShearformTM tech-
nology patented by Fluiz in 1989, whereby partially recrystallized
sugar (used as a carrier) is milled and blended with unprocessed
hydrophilic active compounds and subsequently compressed into
fast disintegrating tablets [29]. However, that process differs from
the one outlined here, whereby we investigate the production of
fully amorphous solid dispersions containing hydrophobic drugs
for dissolution enhancement.
In order to explore the feasibility of the centrifugal spinning
process for producing solid dispersions in the form of fibers, we
describe an inexpensive laboratory scale centrifugal spinning
device involving temperature controlling and calibrating a com-
mercial ‘cotton candy’ machine. In this proof-of-concept study,
we aimed to demonstrate that the use of the centrifugal spinning
approach is an efficient and reliable alternative approach to pro-
duce solid dispersions with enhanced dissolution performance of
two BCS Class II model drugs, olanzapine (OLZ) and piroxicam
(PRX), using sucrose as a carrier. Olanzapine is approved for treat-
ment of psychoses, while piroxicam is a nonsteroidal anti-
inflammatory drugs (NSAIDs) used to treat pain associated with
arthrosis. Both drugs are administered orally as a single dose of
20 mg/day and have shown very low oral bioavailability due to
their poor solubility in water: these are around 43 mg/L for OLZ
(dibasic drug with pKa values of 5.0 and 7.4) [35] and 14 mg/L
for PRX (ampholytic drug with pKa values of 5.1 and 1.9) [36].
Besides the low solubility in water, these drugs were chosen on
the basis of their thermal stability at the processing temperatures
used in this study as supported by other authors [37,38]. The per-
formance of the final products was evaluated, not only in terms of
their ability to enhance the drug dissolution rate (tested under sink
conditions), but also in terms of their ability to generate and main-
tain the supersaturated state (tested under non-sink conditions), as
the latter has shown to be crucial for effective absorption of poorly
water soluble drugs [39–41]).2. Materials and methods
2.1. Materials
Crystalline olanzapine (Mw = 321.43 g mol1) was purchased
from Myjoy Ltd. (India); crystalline piroxicam (Mw = 331.34
g mol1)was purchased fromAfineChemicals Limited (China); crys-
talline sucrose was obtained from Sigma–Aldrich Co. (USA). All
buffer salts used for the dissolution medium, as well as dimethyl
sulfoxide (DMSO), used for drug loading efficiency measurements,
were obtained from Sigma–Aldrich (Germany). All other chemical
reagents were of analytical grade.
Table 1
Summarized technological aspects of the most common methods of solid dispersion preparation compared to the electrospinning and centrifugal spinning processes.
Method Production
rate (lab-scale)
Material choice Method used Disadvantage Application Ref.
Centrifugal spinning 300 g to 6 kg/h Broad Melting/solvent
evaporation
Broad range of
fiber diameter
Fiber glass production, oral thin films, tissue
engineering scaffolds
[25–27,29]
Electro-spinning 0.2–450 g/h Broad but
dependent on
intrinsic properties
of polymer fluid
Mainly solvent
evaporation,
melting
Low production
rate, applied
high voltage, jet
stability
Filtration, tissue engineering, protective
clothing, energy storage, manufacture of
solid dispersions
[18,30]
Hot melt extrusion 100 g to 2 kg/h Broad but
dependent on
thermoplastic
properties of
polymers
Melting Not suitable for
thermally labile
drugs
Rubber/plastic fabrication, pelletized feeds,
implants, injection molding manufacture of
solid dispersions
[31,32]
Spray drying Lower that hot
melt extrusion
Soluble in the
solvent of choice
Solvent
evaporation
Potential solvent
residue
Pharmaceutical materials processing, food
industry, paint pigments, ceramic materials,
catalyst supports, manufacture of solid
dispersions
[33]
Freeze drying Lower than hot
melt extrusion
and spray
drying
Soluble in the
solvent of choice
Solvent
evaporation
Potential solvent
residue, time
consuming
Food industry, treatment of heat sensitive
materials manufacture of solid dispersions
[34]
Fig. 1. Schematic image of the centrifugal spinning device including dimensional
measurements.
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2.2.1. Device optimization and calibration
As illustrated in Fig. 1 the purchased commercial centrifugal
spinning device (ET-MF01 professional, Monster Group, UK)
includes three main parts: an aluminum spinneret (12.2 cm diam-
eter) that rotates about its axis, a heating element and a collector.
The spinneret consists of two main parts: a bottom plate having a
concave cavity configured to receive materials and an upper plate
(2 mm gauge) configured to cover and enclose the concave cavity
such that a gap of 0.8 mm exists between the two plates. Since
the gap is crucial for the consistency of fiber quality and size, the
upper plate was replaced with a thicker 1 cm gauge aluminum
plate to ensure better control of the gap and facilitate the upper
plate removal and cleaning. Once the material is melted and the
rotating speed reaches a critical value, simultaneous centrifugal
and air friction forces overcome the surface tension of the molten
material which is ejected through the gap and stretched into fibers
with decreased surface area.
The centrifugal spinning device was provided with both fixed
rotating speed (2400 rpm, measured using Smiths IndustrialInstruments Ltd. tachometer, UK) and heating temperature
(200 C), as this equipment is generally set to spin sucrose only.
In order to vary the temperature, the machine was modified by
adding an external voltage regulator in the range of 0–250 V. Sub-
sequently, temperature–voltage calibration was performed to
establish the exact temperature range in which the machine can
operate. This was carried out by gradually increasing the voltage
from 0 to 250 V and measuring the temperature at every increment
using a temperature sensor (Testo Mini surface thermometer, ±1 C
accuracy and 0.1 C resolution). Measurements were conducted at
least in triplicate.2.2.2. Sample preparation
Unloaded and 10% (w/w) drug-loaded sucrose microfibers were
prepared as described in Fig. 2 using our modified device. Physical
mixtures (PM) were prepared by mixing sucrose (90 w%) and drug
(10 w%) in a mortar for 5 min. 10 g of starting material were accu-
rately weighed and placed into the spinneret which was preheated
to the required temperature. Spinning operations were conducted
with a rotational speed of 2400 rpm at room temperature
(25 ± 5.0 C). Fibers formed were collected and characterized
within 24 h of preparation.2.2.3. Yield and drug loading efficiency
The percent yield of drug-loaded microfibers was determined
by using Eq. (3).
Yield %
w
w
 
¼ weight of prepared solid dispersion
weight of drugþ carrier  100 ð3Þ
Drug Loading Efficiency (DLE) is defined as follows in Eq. (4):
DLE %
w
w
 
¼ amount of drug measured
theoretical amount of drug based on drug loading
 100
ð4Þ
Drug loading efficiency was measured by dissolving 10 mg of
fibers in 5 mL of DMSO, in which both drug and carrier are soluble,
followed by dilution in phosphate buffer (pH: 6.8) for UV detection.
The amount of drug was calculated using their respective calibra-
tion curves.
Fig. 2. Schematic representation of the centrifugal spinning apparatus and individual process steps in the preparation of drug-loaded microfibers.
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2.2.4.1. Scanning electron microscopy (SEM). Fiber morphology and
diameter were analyzed using a FEITM Quanta 200F Field Emission
SEM. Samples were coated with 20 nm of gold under vacuum using
a Quorum Q150T Turbo-Pumped Sputter Coater. Data were col-
lected over a selected area of the surface of samples. The average
diameter and the percentage frequency of the microfibers were
determined from 100 individual measurements using ImageJ
(USA, version 1.46r). Diameter distribution graphs were plotted
and analyzed using OriginPro 8.0.0.
2.2.4.2. Thermal characterization. Differential scanning calorimetry
(DSC) traces were obtained using a TA Instruments Q2000 (New-
castle, DE, USA) with a refrigerated cooling system attached to a
dry nitrogen sample purge flow at 50 mL/min. Temperature cali-
bration was performed using indium, n-octadecane and tin at both
2 and 10 C/min heating rates; heat capacity constant calibration
was performed using aluminum oxide TA sapphire disks at 2 C/
min with ±0.212 C modulation amplitude and 60 s period. Melting
temperature (Tm) values were obtained using conventional DSC in
which samples were weighed (4–5 mg) into pinholed aluminum
pans (Perkin Elmer) and heated from 0 to 250 C at 10 C/min.
Glass transition (Tg) values were obtained using modulated
temperature DSC (MTDSC) from a heat–cool–heat cycle method
at 2 C/min underlying heating rate with amplitude ±0.212 C
and period 60 s. The Tg was measured in the reheating cycle and
determined as the fictive glass transition temperature using the
TA Instruments proprietary software Universal Analysis.
Water content and thermal decomposition temperature (Tdeg) of
both rawmaterials and formulations weremeasured using thermo-
gravimetric analysis (TGA) with a Q5000 (TA Instruments,
Newcastle, DE, USA). Samples were heated from room temperature
up to 100 C with a heating rate of 10 C/min and held isothermally
for at least 15 min before continuing the heating ramp up to 300 C.
The amount of water content was quantified as the percentage of
mass loss observed in the temperature region below the onset of
degradation.
Hot stage microscopy (HSM) experiments were conducted on a
Leica DML52 microscope with 10–20 magnification lens con-
nected to a FP5/FP52,Mettler Toledo Instruments heating stage unit
and a FP90 Mettler Toledo Instruments central processor unit. HSM
was mainly used to add further confidence to the data obtained
using DSC and TGA. The crystallinity of the samples was evaluated
based on the presence or absence of birefringence under polarized
light at room temperature. Thermal events were recorded using a
JVC color video camera with Studio86 Design capture software.
All measurements were run in triplicate.2.2.4.3. X-ray powder diffraction (XRPD). Ambient X-ray powder
diffraction (XRPD) measurements were performed using a Mini-
Flex diffractometer (RigaKu, Tokyo, Japan). Samples were lightly
pressed into 20 mm aluminum sample trays and the surface was
scraped evenly using a glass slide. A Cu Ka radiation point source
(k = 1.5148 Å) was operated at 40 mV and 15 mA. XRPD patterns
were recorded using diffraction angles (2h) from 10 to 50 (step
size 0.05; time per step 0.2 s). Data was exported and analyzed
using OriginPro 8.0.0. All experiments were conducted in triplicate.
2.2.4.4. Attenuated total reflectance-Fourier transform infrared (ATR-
FTIR). Characterization of fiber molecular structure was performed
using attenuated total reflectance Fourier transform infrared spec-
troscopy (ATR-FTIR) (Bruker Vertex 90 spectrometer). Measure-
ments were performed with a resolution of 2 cm1, 32 scans over
4000–700 cm1 range at room temperature (25 C). Spectra were
analyzed using Opus software version 7.2 and OriginPro 8.0.0. All
experiments were conducted in triplicate.2.2.5. In-vitro dissolution studies
2.2.5.1. Determination of saturation solubility. The thermodynamic
solubility (Cs) is defined as the concentration of a compound in
a saturated solution when an excess of non-dissolved thermody-
namically stable crystals of the compound is in dynamic equilib-
rium with its solution. To evaluate the increase in
thermodynamic solubility of OLZ and PRX from the prepared
solid dispersions, saturation solubility measurements were con-
ducted and compared with those of pure drugs alone and in
the presence of increasing concentrations of sucrose (from 0.5
to 5 mg/mL), according to the method described by Higuchi
and Connors [42]. Known excess amounts of material were
added to glass tubes containing 10 mL of phosphate buffer, pH
6.8. Saturation was confirmed by the presence of undissolved
material. Saturated solutions were stirred in a shake incubator
(SciQuip Mini Incu Shake, UK) at 100 rpm at 37 ± 0.5 C for
48 h in order to achieve equilibrium. Samples of 1 mL were
withdrawn, filtered through a 0.22 lm Millipore Millex GT filter
and properly diluted for UV measurements. All solubility deter-
minations were performed in triplicate. The association constant
(ka) was also calculated using Eq. (5), derived from the slope and
intercept of phase solubility diagram, whereby concentration of
drug dissolved (mol/L) is plotted against the increasing concen-
tration of sucrose (mol/L).
ka ¼ slope
interceptð1 slopeÞ ð5Þ
Table 2
Experimental thermal properties of raw materials measured by DSC and TGA and corresponding process temperatures used for the preparation of microfibers.
Material Melting temperature (C) ± SD Degradation temperature (C) ± SD Water content (%) Process temperature (C)
OLZ 196 ± 0.4 269.7 ± 3.0 0.4 ± 0.12 –
PRX 203 ± 0.2 251.7 ± 2.0 0.04 ± 0.01 –
Sucrose 191 ± 0.5 230.2 ± 4.1 0.72 ± 0.2 197
OLZ–sucrose PM S: 190 ± 0.2
OLZ: 193.1 ± 0.3
234.05 ± 1.0 0.14 ± 0.08 200
PRX–sucrose PM S: 187.1 ± 0.4
PRX: 199 ± 0.6
232.02 ± 3.2 0.1 ± 0.07 205
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solution tests under sink conditions were carried out using a USP
type II paddle apparatus in 500 mL of phosphate buffer (pH: 6.8)
held at a temperature of 37 ± 0.2 C with paddle speed of
100 rpm. OLZ and PRX both show pH-dependent solubility. Since
changes in pH will affect the degree of ionization of such drugs,
and hence their solubility, buffer solutions are generally required
to keep the pH constant. Therefore, for the preliminary study,
phosphate buffer (pH: 6.8) was chosen as a model dissolution med-
ium. The particular pH resembles healthy saliva in the oral cavity
and was chosen on the basis of potential application of these for-
mulations as orally disintegrating tablets. Samples equivalent to
10 mg of drug were encapsulated, without any pre-treatment, in
size 4 gelatin capsules (Qualicaps Europe SA, Madrid) with onset
dissolution of 3 min. At predetermined time intervals, 10 mL sam-
ples were withdrawn from each vessel using a 10 mL syringe and
replaced with fresh medium to maintain a constant total dissolu-
tion volume. The drug concentration in the dissolution medium
was measured using UV detection and the release profile plotted
as percentage of cumulative drug release versus time using Origi-
nPro 8.0.0. No interference from sucrose or gelatin capsules on
the drug assay was observed at the detection wavelengths. For
comparison, dissolution behavior of both pure drugs and corre-
sponding PMs at respective formulation ratios were also studied.
The particle sizes of both PMs and pure drugs were kept constant
by sieving and selecting a 63–125 lm particle size range. All exper-
iments were performed at least in triplicate and the average values
and standard deviations were calculated to plot the dissolution
profiles.2.2.5.3. In-vitro dissolution study under non-sink condi-
tions. Dissolution–supersaturation profiles of the formulations
were obtained by non-sink dissolution tests in phosphate buffer
(pH: 6.8) using a shaking incubator. Samples containing 10 mg of
drug were loaded into 50 mL of dissolution medium. 1 mL samples
were withdrawn at pre-determined time intervals and filtered
through a 0.22 lm Millipore Millex GT filter. The withdrawn vol-
ume was replaced with the same amount of blank dissolution
medium from a separate vessel that had also been held at a
temperature of 37 ± 0.2 C. The absorbance of the filtrate was
measured by UV after appropriate dilution. Dissolution tests were
performed for 4 h, which is approximately the intestinal transit
time in humans [43].3. Results and discussions
3.1. Preparation of centrifugal-spun microfibers
In order to vary the temperature and to allow the spinning of
sucrose in combination with OLZ and PRX, the centrifugal spinning
equipment was modified by adding an external voltage regulator
and temperature calibration performed. As for all extrusion
techniques using heat, the optimal process temperature shouldbe carefully determined on the base of melting (Tm) and degrada-
tion (Tdeg) temperature values of raw materials alone and in their
physical mixtures (PMs) to avoid material degradation or incom-
plete mixing of the drug in the carrier [28,44]. Table 2 shows the
thermal properties of OLZ, PRX and their PMs with sucrose
obtained from DSC and TGA results.
HSM images were also collected during heating to add further
confidence to the DSC data and to visualize complete melting of
each sample. As an example, Fig. S1 shows images of PRX–sucrose
PM captured during heating at 10 C/min from 30 C up to the tem-
perature when complete melting was observed. According to the
HSM images, complete melting of sucrose, OLZ and PRX in the
PMs was observed at 197, 200, and 205 C respectively, which were
slightly higher than Tm values observed in the DSC traces. In addi-
tion, the HSM melting temperature values were found to be dis-
tinct from the degradation temperature values measured using
TGA, observed at 230, 234 and 232 C for sucrose, OLZ–sucrose
and PRX–sucrose PMs respectively and therefore chosen as optimal
spinning temperatures. Using these process conditions, unloaded
and 10% (w/w) drug-loaded sucrose microfibers were successfully
spun using our modified centrifugal spinning device, with relative
high yield (85 ± 5%) and drug loading efficiency (91 ± 5.2% for OLZ
and 79 ± 4.3% for PRX).3.2. Study of surface morphology
Fig. 3 shows the surface morphology of pure sucrose microfi-
bers, and 10% (w/w) OLZ- and PRX-loaded sucrose microfibers,
alongside the corresponding microfiber diameter frequency dia-
grams for each formulation. All formulations show consistent mor-
phology, a relatively small variation in diameter, smooth surface
and random orientation. Moreover, in the case of OLZ- and PRX-
loaded microfibers, the homogeneous morphology and the lack of
visible drug crystals initially suggest that both drugs are molecu-
larly distributed within sucrose microfibers. No statistical differ-
ence in microfiber diameters was found between sucrose (mean
value 9.77 lm) and OLZ-loaded sucrose microfibers (mean value
10.87 lm), whereas a slightly greater diameter was found for
PRX-loaded sucrose microfibers (mean value 14.10 lm). This
might be attributed to the lack of drug–carrier interactions and
the presence of drug molecules entrapped in the free volume
available in the amorphous sucrose matrix [45].3.3. Characterization of physical structure
The diffractograms collected from crystalline raw materials and
microfibers are displayed in Fig. S2. As expected, OLZ, PRX and
sucrose raw materials have a crystalline nature, with sharp intense
peaks throughout their diffraction patterns. However, all freshly
prepared microfibers showed relatively broad halo patterns sug-
gesting only short-range order due to the conversion from the crys-
talline to the amorphous state. The amorphous state was also
confirmed by studying the thermal behavior of the formulations
Fig. 3. SEM images of the surface morphology (500magnification) and microfiber
diameter frequency diagram of (a) unloaded sucrose microfibers, (b) 10% (w/w)
OLZ-loaded sucrose microfibers and (c) 10% (w/w) PRX-loaded sucrose microfibers.
⁄a.d. = average diameter calculated using about 100 individual diameters for each
sample.
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sucrose microfibers are shown in Fig. 4. Sharp endothermic melting
peaks for pure sucrose, OLZ and PRX observed at 191, 196 and
203 C respectively clearly indicate their crystalline nature. AfterFig. 4. MTDSC total heat flow traces of raw materials: (a) sucrose, (b) OLZ and (c)
PRX; and microfibers: (d) sucrose, (e) 10% (w/w) OLZ-loaded sucrose microfibers
and (f) 10% (w/w) PRX-loaded sucrose microfibers with inset view showing
magnification of glass transitions analyzed with reversing heat flow.the spinning process, all microfiber formulations were confirmed
to be in the amorphous state by the presence of a single Tg, fol-
lowed by exothermic crystallization and endothermic melting
peaks. Tg values were observed at 71, 76, and 68 C for sucrose,
OLZ–sucrose and PRX–sucrose microfibers respectively. Moreover,
the presence of a single Tg for both drug-loaded formulations sug-
gests miscibility of the two components at the drug–carrier ratio
under investigation. Interestingly, after exothermic recrystalliza-
tion of drug-loaded microfibers, no melting peak of OLZ was
observed while such a peak was observed for PRX at 202.3 C
(judged to be Form I from comparison with literature data). How-
ever, equivalent solid dispersions, prepared using DSC by melting
respective PMs to just above their melting point and quenching
quickly, did not show any melting endotherm of PRX indicating
that both drugs were molecularly incorporated in the amorphous
state within the sucrose matrix (data not shown). Therefore, this
observation suggests that either the very fast centrifugal spinning
process did not allow complete melting of PRX during microfiber
manufacture or else the PRX partially recrystallized from sucrose
microfibers between manufacture and analysis. It is worth men-
tioning that drugs themselves as well as the presence of water
may act as plasticizers, thereby increasing the possibility of drug
or carrier recrystallization compared to the carrier alone [46],
which may be the case here with PRX. In contrast, the absence of
an OLZ melting peak in the microfibers upon heating suggests that
OLZ was molecularly dispersed within the sucrose microfibers and
remained so during the manufacturing and testing processes.
In order to obtain additional information about the physical
state of freshly prepared microfiber formulations, polarized light
microscopic images of samples were taken at room temperature.
Crystalline and amorphous forms can be distinguished based on
the presence or absence of sample birefringence when observed
under polarized light. Birefringence is generally an indication of
crystallinity whereas amorphous forms show no birefringence.
Images of freshly prepared unloaded and drug-loaded microfibers
are shown in Fig. 5. No birefringence was observed for unloaded
sucrose microfibers, indicating an amorphous form, which was in
agreement with XRPD and DSC results. In contrast, birefringence
was seen in PRX-loaded microfibers and only a trace in OLZ-
loaded microfibers, suggesting the presence of some crystalline
material which was not detected using XRPD. Overall therefore
both systems are very largely amorphous, although there is evi-
dence for the trace presence of crystals, particularly for PRX.
3.4. Spectroscopic characterization of fiber structure
ATR-FTIR is used in this study to further elucidate the physical
state and molecular structure of microfibers as well as identify
potential drug–carrier molecular interactions occurring as a result
of simple mixing or processing at relatively high temperature. FTIR
spectra of pure sucrose, OLZ, PRX and drug loaded microfibers for
OLZ and PRX are shown in Fig. S3. In addition, Table 3 summarizes
ATR-FTIR absorption peak assignments for the drugs alone and in
their PMs with sucrose and 10% w/w drug-loaded microfibers.
The molecular structures of most stable polymorphs for OLZ (Form
I) [47] and PRX (Form I) [48] have already been fully elucidated in
previous studies using ATR-FTIR. The PRX raw material spectrum
shows characteristic peaks (Form I) at 3338, 1628, 1575, 1525
and 1179 cm1 assigned to the m(O–H) vibrations band, m(C@O)
of the amide, m(C@N) of the pyridyl nitrogen and m(N–H) of the ter-
tiary amine and symmetric vibration of SO2, respectively. OLZ raw
material exhibits characteristic peaks (Form I) at 1582 cm1
m(C@N) assigned to the azepine ring, 1556 cm1 m(C@C) of the ben-
zene and thiophene rings and 1411 cm1 due to deformation of
methyl. Peaks in the region between 1600 and 1500 cm1 were
chosen to identify the presence of the drugs in the formulations
Fig. 5. Microscopic images at 20 magnification of freshly prepared microfibers:
(A) unloaded sucrose, (B) 10% (w/w) OLZ-loaded sucrose, (C) 10% (w/w) PRX-loaded
sucrose.
Table 3
ATR-FTIR absorption peak assignments for model drugs alone and in their PMs with
sucrose and 10% w/w drug loaded microfibers.
Absorption band (cm1) Assignment [47–49]
OLZ OLZ–
sucrose PM
OLZ–sucrose
microfibers
2935 2936 2929 C–H stretching
2838 2838 – CH2 symmetric stretching
1582 1583 1588 C@N stretching
1556 1556 1560 Contribution from C@O and C–N
stretching
1142 1143 – Aromatic ring stretching
1411 1409 1406 CH3 deformation
1224 1224 1218 C–N stretching
PRX PRX–
sucrose PM
PRX–sucrose
microfibers
3338 3339 – –OH, –NH stretching
1628 1629 1630 C@O amide carbonyl group
1575 1575 1575 C@N stretching pyridyl nitrogen
1525 1527 1524 C@C stretching of the benzene and
thiophene rings
1179 1180 1180 Symmetric vibration of SO2
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stretching mode bands of sucrose raw material are observed at
3566, 3391, and 3339 cm1 and corresponding O–H deformation
mode bands at 1238, 1209, 1161, and 1342 cm1 [49].
ATR-FTIR spectra of PMs of both drugs with sucrose revealed a
summation of the individual ATR-FTIR spectra of the respective
components with no apparent wavenumber shift of the peaks (data
not shown). This suggests a lack of interaction between drugs and
sucrose in their PM systems. Characteristic peaks of OLZ and PRX
were found in microfiber formulations, confirming the presence
of the drugs in the samples under investigation. The O–H stretch-
ing mode bands of sucrose raw material disappeared in the pure
sucrose microfiber spectrum, suggesting a lack of order in thesucrose molecular structure due to amorphization, as previously
shown from DSC and XRPD results.
Interactions between a drug and a carrier such as hydrogen
bonding or hydrophobic interactions are often considered to be
crucial for producing high quality solid dispersions with acceptable
stability [50]. Sucrose molecules contain free hydroxyl groups
which could act as potential proton donors for hydrogen bonding
with proton acceptor sites present in both OLZ (mainly tertiary
amines from azepine and piperazinyl rings) and PRX (mainly SO2,
amide groups and tertiary amines) molecules. Fig. 6a and b shows
ATR-FTIR spectra of OLZ–sucrose and PRX–sucrose microfibers at
the finger print region of interest. In both formulations, character-
istic peaks of the drugs were found to be fewer in number and
broader than in the spectra of the raw materials, due to the conver-
sion from the crystalline to the amorphous state. In the case of
OLZ–sucrose microfibers, the shift to higher wavenumbers of the
peaks at 1582 and 1556 cm1 assigned to m(C@N) (azepine ring)
and m(C@C) (benzene and thiophene rings) respectively might be
associated with the weakening of OLZ structure due to amorphiza-
tion, whereas the shift of m(C–N) to lower wavenumber from 1224
to 1118 cm1 may suggest a hydrogen bonding interaction
between OLZ and sucrose. In contrast, no chemical shifts were
observed in the case of PRX–sucrose microfibers although charac-
teristic peaks were dramatically lowered in intensity. This might
indicate that low level of crystalline PRX was preserved after
processing. This would be in agreement with the presence of the
melting peak of PRX in the DSC scans and the observation under
microscopy of microcrystalline PRX particles within the sucrose
matrix.3.5. Dissolution study
3.5.1. Phase solubility
Highly hydrophilic excipients such as sugars are well-known
carriers used for solid dispersion-based formulations [51–54]. In
order to examine the aqueous solubility of the model drugs as well
as the potential solubilizing power of sucrose, the equilibrium sol-
ubility of OLZ and PRX was measured in the presence and absence
of sucrose at increasing concentrations (from 0.1 to 5 mg/mL)
according to Higuchi and Connors’s method [42]. The association
constants ðkaÞ and other relevant parameters used in the phase sol-
ubility study are shown in Table 4. Pure OLZ and PRX show similar
solubility values in the absence of sucrose (0.068 and 0.073 mg/mL,
Fig. 6. ATR-FTIR spectra in the region between 1700 and 1000 cm1 of (a) crystalline OLZ (top), OLZ–sucrose microfibers (bottom) and (b) crystalline PRX (top) and PRX–
sucrose microfibers (bottom).
Table 4
Equilibrium solubility of pure OLZ and PRX in phosphate buffer (PBS) (pH: 6.8) at
37 C in the presence and absence of increasing concentrations of sucrose (from 0.1 to
5 mg/mL) and corresponding association constants (ka).
Added sucrose
(mg/mL)
Solubility of OLZ ± SD in
PBS (pH: 6.8) (mg/mL)
Solubility of PRX ± SD in
PBS (pH: 6.8) (mg/mL)
Without sucrose 0.069 ± 0.005 0.073 ± 0.0052
0.1 0.073 ± 0.0049 0.079 ± 0.0045
0.5 0.080 ± 0.0031 0.083 ± 0.0025
2 0.101 ± 0.0029 0.112 ± 0.0047
3 0.127 ± 0.0062 0.155 ± 0.0056
5 0.14 ± 0.0042 0.173 ± 0.006
ka at 37 C (M1) 68.326 (R2 = 0.971) 101.52 (R2 = 0.955)
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sucrose concentration almost linearly (R2 = 0.95–0.97) over the
entire concentration range (0.1–5 mg/mL) (see Fig. S4). The linear-
ity of the phase solubility diagram with slopes lower than one
(0.015–0.02) for both drugs and relatively high association con-
stants (68.33 and 101.52 M1 for OLZ and PRZ, respectively) may
indicate potential formation of 1:1 stoichiometric water soluble
complexes due to hydrogen bonding interactions between both
drugs and sucrose [55,56]. It is therefore evident that sucrose has
some influence on the solubility of the drugs which may contribute
to any subsequent dissolution behavior.3.5.2. Dissolution study under sink conditions
Drug dissolution was initially studied under sink conditions.
Fig. 7a and b compares the dissolution profiles under sink condi-
tions of pure drugs, their corresponding PMs with sucrose and
freshly prepared drug-loaded microfibers, for both OLZ and PRX.
For clarity, time points in which the capsules were still intact (no
drug absorbance was detected using UV) were omitted from the
dissolution profiles of all samples. Significant and similar enhance-
ments in the dissolution rates were observed for both OLZ and
PRX-loaded sucrose microfibers compared to their corresponding
PMs and the pure drugs. Although the rate of drug release from
both PMs is increased compared to the drugs alone, the dissolution
rates of drug-loaded microfibers for both drugs are very distinct
from those of corresponding PMs. In particular, in the case of
OLZ, the times at which 50% and 100% of drug were dissolved
(T50 and T100 respectively) are observed at (1, 4), (8, 30) and (18,
80) min for OLZ-loaded microfibers, PM and pure drug respec-
tively. Similarly for PRX, (T50, T100) values were observed at (1, 3),(4, 35) and (16, 150) min for PRX-loaded microfibers, PM and pure
drug, respectively. Therefore, it is clear that the dissolution rate of
drugs from microfibers is significantly enhanced compared to the
PM systems. Based on these findings, there is no apparent differ-
ence between the dissolution behaviors of the two drug-loaded
microfibers under sink conditions, suggesting that they should also
show similar dissolution performance in vivo. Moreover, given the
very rapid dissolution characteristics, high surface area and low
density observed from both formulations, this approach may be
potentially applicable for the development of orally disintegrating
dosage forms.3.5.3. Dissolution study under non-sink conditions
Fig. 8a and b shows dissolution–supersaturation profiles
obtained under non-sink conditions of the freshly prepared micro-
fiber formulations for OLZ and PRX in comparison with corre-
sponding pure drugs and PMs. Generally under non-sink
conditions, formulations containing metastable amorphous drugs
tend to generate transient supersaturated drug concentration
which inevitably leads to the onset of drug recrystallization and
precipitation, hence a drop in solubility. Depending on the ability
of some functional excipients to act as recrystallization inhibitors,
delay of drug precipitation and stabilization of relatively high
apparent drug solubility can be achieved in solution [57]. This is
generally related to the ‘‘spring and parachute” approach intro-
duced by Guzmán et al., whereby the rapid initial build-up of drug
supersaturation (spring profile) is maintained for a relatively long
time (parachute profile) [58]. In this study, an apparent higher
drug solubility compared to the corresponding pure drugs and
PMs was achieved and maintained with the drug-loaded microfi-
bers for the duration of the dissolution test (4 h) for both drugs.
The absence of a drug concentration decline (i.e. maintenance of
a ‘‘parachute” profile) for both drug-loaded microfibers suggests
that sucrose may prevent the drugs from recrystallizing. A similar
supersaturation profile was reported for tadalafil solid dispersion
in HPMC prepared using freeze drying whereby drug supersatura-
tion remained unchanged for the duration of the dissolution test
due to the inhibitory effect of the carrier [7].
For OLZ, maximal dissolution was observed at 60 min for both
the microfibers and the PM, although the total amount dissolved
was different in the two cases: microfibers reached 0.18 mg/mL
of drug concentration (equal to 90% of the total amount of drug),
whereas only 0.1 mg/mL of drug concentration was reached from
PMs (50% drug dissolution). The drug concentrations obtained in
Fig. 7. Dissolution profiles under sink conditions of (a) OLZ–sucrose fibers compared to corresponding PM and pure drug and (b) PRX–sucrose fibers compared to
corresponding PM and pure drug.
Fig. 8. Dissolution profiles under non-sink conditions of (a) OLZ–sucrose microfibers compared to corresponding PM and pure drug and (b) PRX–sucrose microfibers
compared to corresponding PM and pure drug.
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the microfibers and PM, respectively, taking into account the solu-
bility of OLZ in the absence of sucrose as detailed in Section 3.5.1.
In both cases, the amount of drug measured in solution remained
constant over the remainder of the experimental time period (4 h
in total) with no indication of drug precipitation, showing the
crystallization inhibition behavior of the sucrose. The difference
in dissolution performance of the microfibers and the PM can
be attributed to the amorphous nature and enhanced surface area
of the product, as shown in the MTDSC and XRD studies.
The profile for the PRX microfiber formulation is similar to that
seen with OLZ, but maximal dissolution (only 60% of the total
amount of drug) was observed much earlier, at 15 min, with a
1.7-fold supersaturation. Visually, there appeared to be a slight
decrease in the measured drug concentration over time, but this
was not statistically significant, again showing the protective effect
of sucrose against crystallization. In contrast to the case with OLZ,
drug dissolution from the PRX PM was more gradual, attaining the
same level as the microfibers after 4 h. However, only 16% of the
total amount of drug was dissolved from the PM at 15 min, show-
ing the superior performance of the microfibers. Again, this can be
attributed to the amorphous nature and size reduction of the PRX
in the microfiber formulation.
Overall, the behavior of the formulations is similar in both sink
and non-sink conditions, i.e. there is a rapid initial dissolution ofthe drug from the microfibers with no apparent precipitation over
time, and that the microfiber drug dissolution profile is signifi-
cantly better, in terms of both rate and extent, than that of the
PMs or the pure drugs.
It is necessary to examine the mechanisms behind the benefi-
cial drug dissolution profile of the microfiber formulations. It has
been reported that the rate of supersaturation generation, i.e. the
time taken to reach maximum dissolution and supersaturation,
can significantly affect the achievement of drug supersaturation
and the overall time in which it is maintained [59,60]. In particular,
a high rate of supersaturation build-up generally leads to rapid
nucleation and crystallization in solution. Therefore, the faster rate
of supersaturation generation of PRX–sucrose microfibers com-
pared to OLZ–sucrose microfibers would be thought to induce
rapid crystallization of PRX in solution, leading to drug precipita-
tion and loss of the initial beneficial high dissolution levels. How-
ever, this was not observed here, with the drug concentrations
being maintained over the time course of both dissolution
experiments for both drugs.
In addition, as previously shown in Sections 3.3 and 3.4, low
levels of microcrystalline PRX were found to be present in the
PRX-microfiber formulation. The presence of drug crystals can act
as nuclei for recrystallization, but in the present case, this does
not seem to have resulted in any significant precipitation of PRX.
Another aspect to consider is the potential physico-chemical
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tially impact on the recrystallization process during dissolution. In
particular, relatively strong drug–carrier molecular interactions
could potentially lead to slower drug release in the dissolution
medium and therefore, slower supersaturation build-up and higher
efficacy in maintaining drug supersaturation state. As an example,
Chen et al. [61] carried out a comprehensive investigation of the
drug–polymer–water interactions on the dissolution performance
of various solid dispersion systems. Their study showed that
ketoconazole/HPMC-AS solid dispersion gave the best performance
due to strong drug–polymer interaction in the solid state and the
strength of this interaction against water disruption.
Based on the analysis of the molecular structure of drug-loaded
microfibers using ATR-FTIR reported in Section 3.4, the absence of
OLZ characteristic peaks and chemical shift of m(C–N) to a lower
wavelength in the microfiber formulation suggested that hydrogen
bonding between sucrose and OLZ may have occurred. In contrast,
there is no evidence of formation of hydrogen bonding between
PRX and sucrose in the microfiber formulation. This observation
could explain the slower initial dissolution profile and supersatu-
ration generation for OLZ–sucrose microfibers compared to PRX–
sucrose microfibers. However, although there is a difference in
the dissolution performance between the two drug-loaded micro-
fiber formulations, it is noteworthy that the maximum achievable
drug concentration was rapidly achieved and maintained without
any drop in solubility for all the durations of the dissolution test
for both drugs. This is generally identified as the main driving force
to achieve successful oral absorption in which the rate of dissolu-
tion is the limiting step for systemic absorption [43], and suggests
that both formulations should lead to improved oral bioavailability
compared to conventional solid formulations.4. Conclusions
In this study, we explore the centrifugal spinning process as a
means of rapid production of solid dispersions in the form of
drug-loaded microfibers with enhanced dissolution performance.
Results showed that 10% OLZ- and PRX-loaded microfibers with
high production yield and loading efficiency were successfully pre-
pared using our modified centrifugal spinning machine and the
quality of microfibers formed was assessed using several solid-
state characterization techniques. In particular, SEM images
showed microfibers with homogeneous morphology and lack of
any phase separation suggesting that both drugs were successfully
incorporated into the carrier.
In both sink and non-sink dissolution conditions, there was
noticeable influence of the sucrose carrier on both drug solubility
and dissolution rate when PMs were used compared to the pure
drugs, which indicates good carrier solubilizing capacity. However,
a greater drug dissolution rate and extent were obtained from the
corresponding microfiber formulations which were attributed to
effective reduction in drug particle size, drug amorphization and
enhanced solubility of OLZ and PRX in the presence of sucrose.
Both drug-loaded formulations showed rapid attainment of maxi-
mum drug dissolution with no evidence of drug precipitation over
the time course of the experiment (4 h) representing the average
intestinal transit time, demonstrating an effective parachute
profile.
This suggests that both formulations have potential to increase
the rate and extent of drug released in the absorption site, hence,
improving the oral bioavailability. Therefore, overall, sugar-based
drug-loaded microfibers prepared using centrifugal spinning
showed great potential as an innovative formulation design in
the field of solid dispersions. Moreover, on the basis of the favor-
able dissolution characteristics, this technique could offer a simple,potentially scalable and flexible manufacturing process to produce
orally disintegrating dosage forms.
Our ongoing work is looking at critical factors involved in the
incorporation of centrifugal-spun fibers into oral dosage forms.
These factors include process and material parameters with a par-
ticular attention on chemical stability of formulations, mechanical
properties and effect of excipient on disintegration/dissolution
performance. Our approach aims to analyze these factors using a
multi-scale approach whereby data at different scales (from fibers
to powder to dosage forms) are collected. This approach will hope-
fully enable us to optimize critical factors and produce stable oral
dosage forms with desirable dissolution performance while
lowering the cost of product development and manufacturing.Acknowledgements
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